- Investing Ideas
- U.S. Pharmaceuticals & Biotech Top Growth Stocks
U.S. Pharmaceuticals & Biotech Top Growth Stocks
Results
44
44 companies
Axsome Therapeutics
Market Cap: US$8.1b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$161.17
7D
-3.1%
1Y
29.2%
Madrigal Pharmaceuticals
Market Cap: US$10.1b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$443.18
7D
2.4%
1Y
30.9%
Travere Therapeutics
Market Cap: US$2.6b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$27.76
7D
-3.0%
1Y
39.9%
Zevra Therapeutics
Market Cap: US$579.5m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$9.90
7D
-10.5%
1Y
24.2%
Syndax Pharmaceuticals
Market Cap: US$2.1b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$23.77
7D
-1.6%
1Y
88.5%
Insmed
Market Cap: US$31.2b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$143.93
7D
0.06%
1Y
86.9%
Rhythm Pharmaceuticals
Market Cap: US$6.2b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
RYTM
US$87.68
7D
-5.7%
1Y
67.7%
Ardelyx
Market Cap: US$1.4b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$5.83
7D
-4.7%
1Y
9.6%
ARS Pharmaceuticals
Market Cap: US$863.9m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
SPRY
US$8.89
7D
0.3%
1Y
-22.9%
Capricor Therapeutics
Market Cap: US$1.8b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$31.19
7D
-6.6%
1Y
168.6%
Achieve Life Sciences
Market Cap: US$223.6m
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
ACHV
US$4.25
7D
-0.7%
1Y
52.9%
Pelthos Therapeutics
Market Cap: US$77.7m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$23.85
7D
-5.8%
1Y
50.9%
Corcept Therapeutics
Market Cap: US$3.4b
A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$33.51
7D
-0.09%
1Y
-40.7%
Viridian Therapeutics
Market Cap: US$2.9b
Engages in discovering, developing, and commercializing treatments for serious and rare diseases.
VRDN
US$28.60
7D
-2.0%
1Y
88.9%
Codexis
Market Cap: US$136.3m
Provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.
CDXS
US$1.47
7D
18.5%
1Y
-46.2%
Arcutis Biotherapeutics
Market Cap: US$2.8b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$22.72
7D
-7.6%
1Y
43.2%
Eton Pharmaceuticals
Market Cap: US$509.8m
A pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
ETON
US$18.92
7D
8.7%
1Y
28.9%
CG Oncology
Market Cap: US$5.6b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$68.64
7D
9.3%
1Y
149.8%
AC Immune
Market Cap: US$309.7m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$3.32
7D
9.2%
1Y
48.2%
Kiniksa Pharmaceuticals International
Market Cap: US$3.6b
A biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
KNSA
US$47.02
7D
0%
1Y
108.0%
CollPlant Biotechnologies
Market Cap: US$8.8m
A regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally.
CLGN
US$0.60
7D
-3.4%
1Y
-80.9%
NewAmsterdam Pharma
Market Cap: US$3.4b
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
NAMS
US$30.60
7D
-2.1%
1Y
29.3%
Belite Bio
Market Cap: US$6.5b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.
BLTE
US$161.41
7D
-7.2%
1Y
136.0%
Stoke Therapeutics
Market Cap: US$2.0b
Engages in the development of treatments for severe genetic diseases by upregulating protein expression.
STOK
US$32.87
7D
-14.3%
1Y
270.6%
Invivyd
Market Cap: US$471.9m
Engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States.
IVVD
US$1.59
7D
-13.1%
1Y
97.3%
Verrica Pharmaceuticals
Market Cap: US$106.0m
A dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
VRCA
US$6.31
7D
5.5%
1Y
-2.9%
SIGA Technologies
Market Cap: US$391.2m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$5.02
7D
-11.2%
1Y
-12.8%
Praxis Precision Medicines
Market Cap: US$8.5b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
PRAX
US$303.38
7D
-2.1%
1Y
724.0%
BeOne Medicines
Market Cap: US$32.1b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$287.33
7D
-5.9%
1Y
9.9%
Unicycive Therapeutics
Market Cap: US$150.7m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$6.98
7D
0.4%
1Y
17.4%
Krystal Biotech
Market Cap: US$7.3b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$256.33
7D
-1.8%
1Y
36.0%
Benitec Biopharma
Market Cap: US$411.4m
A clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
BNTC
US$11.75
7D
-4.2%
1Y
-24.3%
Arcellx
Market Cap: US$6.7b
Together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.
ACLX
US$114.52
7D
0.1%
1Y
63.9%
Amicus Therapeutics
Market Cap: US$4.5b
A biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.
FOLD
US$14.37
7D
0.07%
1Y
60.0%
Prelude Therapeutics
Market Cap: US$277.3m
A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
PRLD
US$3.43
7D
-4.7%
1Y
384.5%
Journey Medical
Market Cap: US$247.8m
Focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$7.50
7D
-8.0%
1Y
40.7%